Exagen Inc
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing produc… Read more
Exagen Inc (XGN) - Net Assets
Latest net assets as of September 2025: $18.14 Million USD
Based on the latest financial reports, Exagen Inc (XGN) has net assets worth $18.14 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($62.82 Million) and total liabilities ($44.69 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $18.14 Million |
| % of Total Assets | 28.87% |
| Annual Growth Rate | 5.85% |
| 5-Year Change | -77.2% |
| 10-Year Change | N/A |
| Growth Volatility | 1117.31 |
Exagen Inc - Net Assets Trend (2012–2024)
This chart illustrates how Exagen Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Exagen Inc (2012–2024)
The table below shows the annual net assets of Exagen Inc from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $9.54 Million | -57.96% |
| 2023-12-31 | $22.69 Million | -46.55% |
| 2022-12-31 | $42.46 Million | -50.01% |
| 2021-12-31 | $84.94 Million | +103.01% |
| 2020-12-31 | $41.84 Million | -24.83% |
| 2019-12-31 | $55.66 Million | +926.54% |
| 2018-12-31 | $-6.73 Million | -45.19% |
| 2017-12-31 | $-4.64 Million | +79.09% |
| 2015-12-31 | $-22.18 Million | -57.83% |
| 2014-12-31 | $-14.06 Million | -3216.63% |
| 2013-12-31 | $451.00K | -90.65% |
| 2012-12-31 | $4.82 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Exagen Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 23353900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $18.00K | 0.19% |
| Other Components | $303.85 Million | 3185.04% |
| Total Equity | $9.54 Million | 100.00% |
Exagen Inc Competitors by Market Cap
The table below lists competitors of Exagen Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BioSmart Co.Ltd
KQ:038460
|
$46.07 Million |
|
Dynamic Cables Limited
NSE:DYCL
|
$46.07 Million |
|
Midsona AB Series B
LSE:0GSE
|
$46.08 Million |
|
Marblegate Acquisition Corp
NASDAQ:GATE
|
$46.10 Million |
|
Signpost India Limited
NSE:SIGNPOST
|
$46.05 Million |
|
Hedef Girisim Sermayesi
IS:HDFGS
|
$46.05 Million |
|
Tantalus Systems Holding Inc
OTCQX:TNTLF
|
$46.03 Million |
|
Dynacons Systems & Solutions Limited
NSE:DSSL
|
$46.02 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Exagen Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 22,694,000 to 9,540,000, a change of -13,154,000 (-58.0%).
- Net loss of 15,115,000 reduced equity.
- Share repurchases of 176,000 reduced equity.
- Other factors increased equity by 2,137,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-15.12 Million | -158.44% |
| Share Repurchases | $176.00K | -1.84% |
| Other Changes | $2.14 Million | +22.4% |
| Total Change | $- | -57.96% |
Book Value vs Market Value Analysis
This analysis compares Exagen Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.05x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.02x to 6.05x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $136.19 | $3.17 | x |
| 2013-12-31 | $8.40 | $3.17 | x |
| 2014-12-31 | $-249.38 | $3.17 | x |
| 2015-12-31 | $-353.27 | $3.17 | x |
| 2017-12-31 | $-73.61 | $3.17 | x |
| 2018-12-31 | $-106.88 | $3.17 | x |
| 2019-12-31 | $4.43 | $3.17 | x |
| 2020-12-31 | $3.31 | $3.17 | x |
| 2021-12-31 | $5.32 | $3.17 | x |
| 2022-12-31 | $2.49 | $3.17 | x |
| 2023-12-31 | $1.28 | $3.17 | x |
| 2024-12-31 | $0.52 | $3.17 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Exagen Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -158.44%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -27.17%
- • Asset Turnover: 1.25x
- • Equity Multiplier: 4.68x
- Recent ROE (-158.44%) is above the historical average (-300.99%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -151.89% | -790.93% | 0.08x | 2.34x | $-7.81 Million |
| 2013 | -2992.46% | -441.77% | 0.19x | 36.48x | $-13.54 Million |
| 2014 | 0.00% | -128.45% | 0.68x | 0.00x | $-13.58 Million |
| 2015 | 0.00% | -106.89% | 1.23x | 0.00x | $-16.96 Million |
| 2017 | 0.00% | -95.61% | 1.31x | 0.00x | $-25.17 Million |
| 2018 | 0.00% | -24.70% | 1.12x | 0.00x | $-7.34 Million |
| 2019 | -21.63% | -29.81% | 0.46x | 1.59x | $-17.60 Million |
| 2020 | -39.88% | -39.75% | 0.54x | 1.87x | $-20.87 Million |
| 2021 | -31.61% | -55.59% | 0.39x | 1.45x | $-35.34 Million |
| 2022 | -111.60% | -104.00% | 0.53x | 2.03x | $-51.63 Million |
| 2023 | -104.38% | -45.08% | 0.92x | 2.51x | $-25.96 Million |
| 2024 | -158.44% | -27.17% | 1.25x | 4.68x | $-16.07 Million |
Industry Comparison
This section compares Exagen Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Exagen Inc (XGN) | $18.14 Million | -151.89% | 2.46x | $46.05 Million |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |